{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:12Z","timestamp":1780920612970,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":81,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101192","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:22:11Z","timestamp":1774286531000},"page":"101192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Barriers to clinical implementation for novel therapies and biomarker testing in the community practice oncology setting: A CLDN18.2 case study"],"prefix":"10.1016","volume":"47","author":[{"given":"Aditya","family":"Shreenivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101192_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers."},{"key":"10.1016\/j.ctarc.2026.101192_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101192_bib0003","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101192_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctarc.2026.101192_bib0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101192_bib0006","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101192_bib0007","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101192_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101192_bib0009","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"issue":"104000","key":"10.1016\/j.ctarc.2026.101192_bib0010","article-title":"Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer","volume":"9","author":"Kim","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctarc.2026.101192_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101192_bib0012","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101192_bib0013","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101192_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/EDBK_175231","article-title":"Immunotherapy for esophageal and gastric cancer","volume":"37","author":"Kelly","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.ctarc.2026.101192_bib0016","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/annonc\/mdx051","article-title":"New agents on the horizon in gastric cancer","volume":"28","author":"Lordick","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101192_bib0017","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2026.101192_bib0018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","article-title":"Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial","volume":"24","author":"Khoury","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:38:51Z","timestamp":1780918731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"alternative-id":["S2468294226001036"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101192","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to clinical implementation for novel therapies and biomarker testing in the community practice oncology setting: A CLDN18.2 case study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101192"}}